154 related articles for article (PubMed ID: 36853631)
1. Expanding Access to Oral Preexposure Prophylaxis for People Who Inject Drugs in Bayelsa and Niger States, Nigeria.
Nishimoto L; Ikani P; Achanya J; Idowu A; Olisa AL; Walker CF; Gottlieb A; Akolo C
Glob Health Sci Pract; 2023 Feb; 11(1):. PubMed ID: 36853631
[TBL] [Abstract][Full Text] [Related]
2. Service utilization and cost of implementing a comprehensive HIV prevention and care program among people who inject drugs in Delhi, India.
Sebastian MP; Dasgupta A; Saraswati LR; Singh A; Sharma V; Madan I; Tun W; Pulerwitz J; Thior I; Sarna A
Harm Reduct J; 2017 Jun; 14(1):38. PubMed ID: 28615077
[TBL] [Abstract][Full Text] [Related]
3. Missed opportunities for healthcare providers to discuss HIV preexposure prophylaxis with people who inject drugs.
Vincent W; McFarland W
Int J Drug Policy; 2022 Dec; 110():103873. PubMed ID: 36252292
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of an inner city HIV pre-exposure prophylaxis service tailored to the needs of people who inject drugs.
Grimshaw C; Boyd L; Smith M; Estcourt CS; Metcalfe R
HIV Med; 2021 Nov; 22(10):965-970. PubMed ID: 34585494
[TBL] [Abstract][Full Text] [Related]
5. An Exploration of Factors Impacting Preexposure Prophylaxis Eligibility and Access Among Syringe Exchange Users.
Roth AM; Aumaier BL; Felsher MA; Welles SL; Martinez-Donate AP; Chavis M; Van Der Pol B
Sex Transm Dis; 2018 Apr; 45(4):217-221. PubMed ID: 29465703
[TBL] [Abstract][Full Text] [Related]
6. "Take services to the people": strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda.
Kamusiime B; Beima-Sofie K; Chhun N; Nalumansi A; Nalukwago GK; Kasiita V; Twesige CC; Kansiime R; Muwonge TR; Kyambadde P; Kadama H; Mudiope P; Glick S; Lambdin B; Mujugira A; Heffron R
Addict Sci Clin Pract; 2024 Feb; 19(1):13. PubMed ID: 38395940
[TBL] [Abstract][Full Text] [Related]
7. Pre-exposure prophylaxis (PrEP) for HIV prevention among people who inject drugs: a global mapping of service delivery.
Shaw G; Schaefer R; Schmidt HA; Madden A; Chang J; Mozalevskis A; Msimanga-Radebe B; Mangadan Konath N; Verster A; Baggaley R; Rodolph M; Macdonald V
Harm Reduct J; 2023 Feb; 20(1):16. PubMed ID: 36782321
[TBL] [Abstract][Full Text] [Related]
8. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs.
Biello KB; Bazzi AR; Mimiaga MJ; Biancarelli DL; Edeza A; Salhaney P; Childs E; Drainoni ML
Harm Reduct J; 2018 Nov; 15(1):55. PubMed ID: 30419926
[TBL] [Abstract][Full Text] [Related]
9. HIV Pre-Exposure Prophylaxis Prevention Awareness, Willingness, and Perceived Barriers among People Who Inject Drugs in Los Angeles and San Francisco, CA, 2016-2018.
Walters SM; Kral AH; Simpson KA; Wenger L; Bluthenthal RN
Subst Use Misuse; 2020; 55(14):2409-2419. PubMed ID: 32962490
[TBL] [Abstract][Full Text] [Related]
10. Expansion of Preexposure Prophylaxis Capacity in Response to an HIV Outbreak Among People Who Inject Drugs-Cabell County, West Virginia, 2019.
Furukawa NW; Weimer M; Willenburg KS; Kilkenny ME; Atkins AD; Paul McClung R; Hansen Z; Napier K; Handanagic S; Carnes NA; Kemp Rinderle J; Neblett-Fanfair R; Oster AM; Smith DK
Public Health Rep; 2022; 137(1):25-31. PubMed ID: 33646890
[TBL] [Abstract][Full Text] [Related]
11. Limited Knowledge and Mixed Interest in Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs.
Bazzi AR; Biancarelli DL; Childs E; Drainoni ML; Edeza A; Salhaney P; Mimiaga MJ; Biello KB
AIDS Patient Care STDS; 2018 Dec; 32(12):529-537. PubMed ID: 30311777
[TBL] [Abstract][Full Text] [Related]
12. Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.
Bartholomew TS; Plesons M; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; Chueng TA; Ciraldo K; Brooks J; Smith JD; Barocas JA; Tookes HE
Addict Sci Clin Pract; 2024 Mar; 19(1):21. PubMed ID: 38528570
[TBL] [Abstract][Full Text] [Related]
13. Brief Report: Use of Pre-Exposure Prophylaxis to Prevent Rapid HIV Transmission Among People Who Inject Drugs in Rural Counties in the United States: A Modeling Study.
Jacka BP; Nolen S; Bessey SE; Zang X; Goedel WC; Yedinak JL; Marshall BDL
J Acquir Immune Defic Syndr; 2022 Dec; 91(5):449-452. PubMed ID: 36150038
[TBL] [Abstract][Full Text] [Related]
14. Awareness of and willingness to use pre-exposure prophylaxis (PrEP) among people who inject drugs and men who have sex with men in India: Results from a multi-city cross-sectional survey.
Belludi A; McFall AM; Solomon SS; Celentano DD; Mehta SH; Srikrishnan AK; Kumar MS; Solomon S; Lucas GM
PLoS One; 2021; 16(2):e0247352. PubMed ID: 33630909
[TBL] [Abstract][Full Text] [Related]
15. Qualitative inquiry into perceptions of HIV pre-exposure prophylaxis among people who inject drugs living with hepatitis C in Seattle, WA, USA.
Barry MP; Austin EJ; Bhatraju EP; Glick SN; Stekler JD; Tung EL; Hansen RN; Williams EC; Gojic AJ; Pickering EI; Tsui JI
Harm Reduct J; 2022 Nov; 19(1):121. PubMed ID: 36320005
[TBL] [Abstract][Full Text] [Related]
16. M
Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
[TBL] [Abstract][Full Text] [Related]
17. Patient and Provider Perspectives on a Novel, Low-Threshold HIV PrEP Program for People Who Inject Drugs Experiencing Homelessness.
Bazzi AR; Shaw LC; Biello KB; Vahey S; Brody JK
J Gen Intern Med; 2023 Mar; 38(4):913-921. PubMed ID: 35614171
[TBL] [Abstract][Full Text] [Related]
18. Continuing Low Awareness and Use of Pre-exposure Prophylaxis (PrEP) for HIV among People Who Inject Drugs (PWID), San Francisco, 2022.
Suprasert B; Tate M; Reagan D; Ruiz R; Gao K; McNaughton K; Miller K; Marr A; Taylor KD; Wilson EC; McFarland W
AIDS Behav; 2024 Jun; 28(6):2089-2100. PubMed ID: 38526638
[TBL] [Abstract][Full Text] [Related]
19. Contingency Management and Pre-Exposure Prophylaxis Adherence Support Services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs.
Sung ML; Viera A; Esserman D; Tong G; Davidson D; Aiudi S; Bailey GL; Buchanan AL; Buchelli M; Jenkins M; John B; Kolakowski J; Lame A; Murphy SM; Porter E; Simone L; Paris M; Rash CJ; Edelman EJ
Contemp Clin Trials; 2023 Feb; 125():107037. PubMed ID: 36460267
[TBL] [Abstract][Full Text] [Related]
20. Evidence of Potential Discriminatory HIV Pre-Exposure Prophylaxis (PrEP) Prescribing Practices for People Who Inject Drugs Among a Small Percentage of Providers in the U.S.
Pleuhs B; Mistler CB; Quinn KG; Dickson-Gomez J; Walsh JL; Petroll AE; John SA
J Prim Care Community Health; 2022; 13():21501319211063999. PubMed ID: 35068243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
